Russell Investments Group Ltd. Decreases Stock Position in Inhibrx, Inc. (NASDAQ:INBX)

Russell Investments Group Ltd. lowered its position in Inhibrx, Inc. (NASDAQ:INBX) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 435,450 shares of the company’s stock after selling 23,606 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.92% of Inhibrx worth $16,547,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. lifted its position in shares of Inhibrx by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 27,731 shares of the company’s stock worth $509,000 after purchasing an additional 13,098 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Inhibrx during the 3rd quarter worth about $232,000. Swiss National Bank boosted its position in shares of Inhibrx by 2.1% during the 3rd quarter. Swiss National Bank now owns 57,600 shares of the company’s stock worth $1,057,000 after acquiring an additional 1,200 shares in the last quarter. Citigroup Inc. increased its holdings in shares of Inhibrx by 3.4% in the 3rd quarter. Citigroup Inc. now owns 49,244 shares of the company’s stock valued at $904,000 after acquiring an additional 1,611 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Inhibrx during the 3rd quarter worth about $7,964,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Stock Up 0.4 %

Shares of NASDAQ INBX opened at $34.15 on Friday. The business has a 50-day moving average price of $35.11 and a 200 day moving average price of $30.81. The stock has a market cap of $1.79 billion, a PE ratio of -6.79 and a beta of 2.87. The company has a quick ratio of 5.25, a current ratio of 5.24 and a debt-to-equity ratio of 4.78. Inhibrx, Inc. has a 52-week low of $14.31 and a 52-week high of $39.79.

Inhibrx (NASDAQ:INBX) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.66). The firm had revenue of $1.63 million during the quarter, compared to analyst estimates of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. Equities research analysts forecast that Inhibrx, Inc. will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

INBX has been the subject of a number of research analyst reports. Lifesci Capital downgraded Inhibrx from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 23rd. JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research report on Tuesday, January 23rd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.